Back to search
FDAFDA · Food and drugs·Recall number D-0101-2025

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottle, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08

Published December 11, 2024 · Recall initiated: November 14, 2024

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
PA, OH, PR
Lot
Lot, expiry: DT6022159A, DT6022167A, DT6022168A, exp 11/30/2024; Lot DT6023034A, 12/31/2024; Lots DT6023050A, DT6023051A, DT6023063A, DT6023067A, exp 01/31/2025; Lots DT6023073A, DT6023072A, exp 02/28/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Sell products like this?

Recalert watches your whole catalog for recalls like this one, automatically.

Start free — no card